HAYA Therapeutics

“Programming Lasting Health” — RNA-guided therapies that reprogram disease-driving cell states to restore health by targeting the regulatory genome (non-coding RNA) rather than just managing symptoms.

Where it wins

• Causal vs. Symptomatic: Moves beyond traditional small molecules or protein-targeting biologics by targeting long non-coding RNAs (lncRNAs) that causally drive disease at the cellular level [1][2].
• Programmable Precision: Uses a proprietary platform to decode the “dark genome” (98% of non-coding DNA) to identify tissue- and cell-specific targets, aiming for higher efficacy and lower toxicity [3][2].
• First-in-Class Lead Asset: HTX-001 is a first-in-class lncRNA-targeting therapy for non-obstructive hypertrophic cardiomyopathy (nHCM), backed by FDA Fast Track Designation [1][2].
• Validated by Pharma Giants: A $1 billion collaboration with Eli Lilly validates the platform’s potential in high-value indications like obesity and metabolic disorders [3].

Credibility: FDA Fast Track Designation for HTX-001 [1]; $1B Lilly collaboration [3]; $65M Series A led by Sofinnova Partners [2].

• Platform-driven discovery: Uses a proprietary stack of multimodal functional genomics and machine learning to map the regulatory genome and identify novel lncRNA targets [2].
• Target-to-therapy pipeline: Translates identified targets into RNA-guided therapeutic candidates (like HTX-001) that reprogram cell states [1][2].
• Strategic collaborations: Partners with major pharma (e.g., Lilly) to co-develop therapies in high-value indications, sharing risk and reward [3].
• Scientific IP moat: Builds a comprehensive atlas of the regulatory genome, creating a defensible data and IP position in a novel therapeutic space [2].
• Dual-site operations: Combines Swiss scientific leadership (Lausanne) with US clinical and commercial execution (San Diego) [1][2].

• Traditional pharma: Companies using small molecules or protein-targeting biologics; HAYA offers a novel, causal approach via lncRNAs [3][2].
• Gene therapy companies: Firms targeting DNA or mRNA; HAYA’s RNA-guided platform offers programmable precision and potentially better safety [1][2].
• Biotech startups in regulatory genome: Few competitors are targeting the dark genome at scale; HAYA’s atlas and platform provide a first-mover advantage [2].
• Obesity drug developers: Companies like Novo Nordisk and Eli Lilly (in other programs) face competition from HAYA’s potential for higher efficacy and safety [3].
• Differentiators: HAYA’s unique platform, FDA Fast Track status, and $1B Lilly partnership validate its approach in a space with limited direct competitors [1][3][2].

• Unmet need in rare cardiometabolic diseases: Patients with nHCM and heart failure lack disease-modifying therapies [2].
• Limitations of current metabolic treatments: Existing obesity and metabolic drugs often have efficacy and safety issues [3].
• Symptom-focused care: Most current therapies manage symptoms rather than addressing root causes [1].
• Complexity of the regulatory genome: The “dark genome” has been underexplored due to technical challenges, leaving a vast therapeutic potential untapped [2].
• High burden of chronic diseases: Age-related and chronic conditions place a massive economic and health burden on healthcare systems [2].

HAYA is positioning itself as a platform company in a nascent therapeutic space, leveraging a $1B partnership to de-risk and validate its science. The main risk is the technical complexity of targeting lncRNAs and the long timeline for clinical success. The opportunity lies in expanding the platform into high-value indications like obesity and cancer. The next signal to watch is the Phase 1 data for HTX-001, which will prove the platform’s clinical viability.

HAYA should accelerate the expansion of its platform into additional indications beyond cardiovascular and metabolic diseases, such as oncology and pulmonary fibrosis, to diversify risk. The company should invest in patient advocacy and awareness campaigns for nHCM to build a pipeline of trial participants and long-term brand loyalty. HAYA should explore licensing its platform to mid-sized biotechs for earlier-stage target discovery, creating a new revenue stream and broader ecosystem validation. The company should strengthen its regulatory strategy by engaging with the FDA earlier for platform-wide guidance, not just for HTX-001, to streamline future approvals.